Bastide Le Confort Medical


Sound H1 results, solid deleveraging, and reaffirmed FY guidance

19/03/26 -"Bastide’s H1 results delivered underlying indicators on track towards FY targets, with a net profit from discontinued activities, primarily the Baywater sale, exceeding our expectations. ..."

Pages
49
Language
English
Published on
19/03/26
You may also be interested by these reports :
19/03/26
Bastide’s H1 results delivered underlying indicators on track towards FY targets, with a net profit from discontinued activities, primarily the ...

19/03/26
MedTechs remain a disaster story – held back by a series of never-ending headwinds, like supply chain, interest rates, slowing China, tariffs etc., ...

18/03/26
We have revised our earnings estimates downward due to ongoing business weaknesses and persistent macroeconomic challenges, which continue to weigh ...

18/03/26
While medium-to-long-term targets appear credible – which also reflect in the upside on fundamental valuation metrics (i.e. DCF and NAV), the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO